Androgen receptor (AR) is ligand-inducible nuclear hormone receptor which has been focused on key molecular target in growth and progression of prostate cancer. We synthesized a series of 4-aryl 2-substituted aniline-thiazole analogs and evaluated their anti-cancer activity in AR-dependent human prostate cancer LNCap cells. Among them, the compound 6 inhibited the tumor growth in LNCap-inoculated xenograft model.
Introduction
Androgen receptor (AR) is androgen inducible nuclear hormone receptor and a key molecular target in growth and progression of prostate cancer, even at the castrationresistant status.
1,2 Prostate cancer (PCa) is the most common cancer form related to death in men. 3 Nonsteroidal AR antagonists, preventing androgens from binding AR in the prostate, have been extensively developed during the past years. 4, 5 The results of research and development are exemplified by several marketed drugs as androgen receptor antagonist including Schering-Plough' flutamide ( Figure 1 . Recent troubleshooting in AR antagonist development is that reactivation of the AR signaling pathway causes the development of androgen independent prostate cancer. Therefore, we were going to identify new small molecule antagonists of the AR that are more effective than the current AR antagonists. Our primary screening efforts produced a series of thiazole-based compound in AR dependent LNCap cell line, and then we investigated in vivo activity.
Experimental Section
The 4-aryl-2-anilino-thiazole derivative was identified as putative androgen receptor (AR) antagonist for the treatment of prostate cancer through high-throughput screening (HTS) using the chemical library of Korea Chemical Bank ( Figure  2 ). Furthermore, we synthesized its derivatives to address moiety of which could be attributing to their biological activity.
According to the Scheme 1, we synthesized 10 compounds, as follows. All of the 10 compounds were synthesized according to the similar methods described in literatures. 6 The synthetic route of 4-aryl 2-substituted aniline-thiazole analogs is shown in Scheme 1. Commercially available acetophenones 11 was brominated with Br 2 in CH 2 Cl 2 to afford -bromo acetophenones 12. Reaction of -bromoketones 12 with NaSCN in EtOH, followed by condensation with appropriate substituted-anilines 13 under reflux condition gave the desired 2-anilino thiazoles 1-4 in moderate yield. Alternatively, coupling reaction of benzoylisothioa These authors contributed equally to this work. Figure 2 . The early hit structure (89% inhibition at 10 uM) obtained from the high-throughput screening using in-house library.
cyanate with various anilines 13 was carried out in acetone, and then hydrolyzed with 2N-NaOH to afford substituted arylthioureas 14, which was reacted with 12 in refluxing ethanol to give desired compounds 1-10, as shown in Table  1 , in good yield.
7

Results and Discussion
The effect of compounds on the viability of human prostate AR-positive LNCap cells were evaluated.
8 Cell viability assay revealed that the compounds 5, 6, and 9 showed the potent inhibitory activity in the viability of LNCap cells, having stronger or similar activities to the reference compound, bicalutamide. Before evaluating the therapeutic activity of 4-aryl 2-substituted aniline-thiazole analogs in the AR-positive prostate cancer, we further determined physicochemical properties, 9,10 metabolic stability 11 and CYP inhibition activity 12 of compound 5, 6, and 9 that strongly inhibited the viability of LNCap cell. As shown in Table 2 , two compounds, 5 and 6 showed appropriate logP values and medium permeability against artificial permeable membrane, while compound 11 showed lower logP value though having good activity. Here we decided the compound 6 and 7 with proper logP value that well correlate the solubility and permeability and similar activity to reference compound come into the further study. Additionally, we tested metabolic stability and CYP effect. Both compounds did not show the strong CYP inhibition activity, but in evaluation for metabolic stability in rat, the compound 6, with 99% of the parent compound remaining after 1 h incubation, showed to be more stable than the compound 5. Based on the reported data, we chose the compound 6 for further in vivo study. Figure 3 . Effect of compound 6 on tumor growth in LNCapinoculated xenograft model.
Next, the therapeutic activity of the compound 6 was evaluated in LNCap-inoculated xenograft model. 13 As shown in Figure 3 , the compound 6 attenuated the tumor growth as observed in the bicalutamide-treated group, suggesting its in vivo inhibitory effect on the growth of AR-positive prostate cancer.
Also, we carried out the docking study to confirm the AR binding mode for compound 6. The AR complex structure as reference was obtained from the x-ray crystal structure of the mutant W741L AR bound to bicalutamide (pdb code: 1Z95), 14 replacing Leu741 in 1Z95 by the wild-type Trp, with adjustment of the conformation of the nearby Met895.
Docking study was carried out using LigandFit 15 module in DiscoveryStudio 3.1 with CHARMM force field. The experimental binding conformation of bicalutamide was well created showing score value of 65.28 with Dock_Score in LigandFit. Compound 6 was well fitted in the binding site with the Dock_Score of 50.91 as shown in Figure 4 . The two terminal nitro groups also have H-bonding interactions with Arg752 and two water molecules such as bicalutamide. As docking study, we can confirm compound 6 interacts with AR binding site in vitro.
Conclusion
In this paper, we synthesized a series of 4-aryl 2-substituted aniline-thiazole analogs showing the similar binding mode to bicalutamide and evaluated their anti-cancer activity in AR-dependent human prostate cancer LNCap cells. Among them, the compound 6 inhibited the tumor growth in LNCap-inoculated xenograft model. Furthermore, we are going to deeply optimize for our compounds to develop the drug for prostate cancer treatment. 
